| 0.2154 -0.015 (-6.31%) | 10-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Kintara Therapeutics, Inc. operates as a clinical-stage biotechnology firm, dedicated to pioneering and commercializing anti-cancer treatments for patients. Central to its pipeline are two compounds nearing Phase III trials. One, VAL-083, is a DNA-targeting agent developed to combat drug-resistant solid tumors, including challenging conditions like glioblastoma multiforme, alongside other solid tumor types such as ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other, REM-001, is a photodynamic therapy specifically targeting cutaneous metastatic breast cancer. The company has forged a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to facilitate the production and sale of VAL-083 within the Chinese market. Incorporated in 2009, Kintara maintains its headquarters in San Diego, California. Its current identity as Kintara Therapeutics, Inc. was adopted in August 2020, succeeding its former name, DelMar Pharmaceuticals, Inc.
Wed, 16 Oct 2024
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - prnewswire.com
Fri, 20 Sep 2024
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 - Stock Titan
Wed, 26 Jun 2024
Kintara Therapeutics (NASDAQ: KTRA) - Share Price - intelligentinvestor.com.au
Tue, 14 May 2024
KTRA Stock Earnings: Kintara Therapeutics Reported Results for Q3 2024 - TradingView
Thu, 22 Feb 2024
Kintara Therapeutics Halts ATM Offerings and Equity Facility Usage - TipRanks
Sat, 22 Jul 2023
Kintara Therapeutics: KTRA Stock Price Quote & News - Robinhood
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|